Dublin, June 12, 2023 (GLOBE NEWSWIRE) -- The "Pediatric Neuroblastoma Treatment Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the market.
The global pediatric nerublastoma treatment market is expected to grow from $1.52 billion in 2022 to $1.67 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The pediatric neuroblastoma treatment market is expected to reach $2.37 billion in 2027 at a CAGR of 9.1%.
Major players in the pediatric neuroblastoma treatment market are United Therapeutics Corporation, APEIRON Biologics AG, Baxter International Inc., Cell Ectar Biosciences Inc., Pfizer Inc., MacroGenics Inc., Bayer AG, Provectus Biopharmaceuticals Inc., Sartorius AG, Y-mAbs Therapeutics Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Clarity Pharmaceuticals, and CureSearch for Children's Cancer.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Paediatric neuroblastoma treatment refers to a kind of treatment for cancer or a tumor that affects the nervous system in children. Neuroblastoma is typically treated with a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy.
The main types of pediatric neuroblastoma treatments are immunotherapy, chemotherapy, radiation therapy, and others. Immunotherapy is a form of medical treatment that uses the immune system's power to fight disease. It is used to treat several risk groups, such as low risk, intermediate risk, and high risk, and is used by various end users including hospitals, specialty clinics, and others.
The pediatric neuroblastoma treatment market research report is one of a series of new reports that provides pediatric neuroblastoma treatment market statistics, including pediatric neuroblastoma treatment industry global market size, regional shares, competitors with a pediatric neuroblastoma treatment market share, detailed pediatric neuroblastoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric neuroblastoma treatment industry. This pediatric neuroblastoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Research and development are the key trend gaining popularity in the pediatric neuroblastoma treatment market. Major companies operating in the pediatric neuroblastoma treatment market are focusing on advance research and development to sustain their position in the market.
In March 2022, Recordati S.p.A., an Italy-based pharmaceutical group, acquired EUSA Pharma (UK) Ltd. for $824.28 million. The acquisition is expected to offer Recordati a broader portfolio of pharmaceuticals for rare diseases. EUSA Pharma (UK) Ltd. is a UK-based specialty pharmaceutical company that deals in pediatric neuroblastoma treatment.
North America was the largest region in the pediatric neuroblastoma treatment market in 2022. The regions covered in pediatric neuroblastoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the pediatric neuroblastoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The rising number of new cases of pediatric neuroblastoma is expected to propel the growth of the pediatric neuroblastoma treatment market going forward. The rising prevalence of neuroblastoma is increasing the demand for pediatric neuroblastoma treatment alternatives.
As a result, pharmaceutical corporations and other stakeholders have boosted their investment in research and development, promoting innovation in the industry. Furthermore, the availability of new diagnostic technology and screening procedures has resulted in earlier neuroblastoma discovery, allowing for earlier treatments and better outcomes.
For instance, in March 2023, according to an article published by the American Society of Clinical Oncology (ASCO), a US-based organization for oncology professionals and physicians, neuroblastoma affects approximately 700 to 800 youngsters in the United States each year. In the United States, neuroblastoma accounts for 6% of all childhood malignancies.
Neuroblastoma affects around 90% of children under the age of five. Therefore, the rising number of new cases of pediatric neuroblastoma is driving the growth of the pediatric neuroblastoma treatment market.
The pediatric neuroblastoma treatment market consists of revenues earned by entities by providing pediatric neuroblastoma treatment services such as stem cell therapy, supportive care and blood transfusions. The market value includes the value of related goods sold by the service provider or included within the service offering. The pediatric neuroblastoma treatment market also includes sales of pain management medications, chemotherapy drugs and immunotherapy agents which are used in providing pediatric neuroblastoma treatment services.
Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 275 |
| Forecast Period | 2023 - 2027 |
| Estimated Market Value (USD) in 2023 | $1.67 billion |
| Forecasted Market Value (USD) by 2027 | $2.37 billion |
| Compound Annual Growth Rate | 9.1% |
| Regions Covered | Global |
Key Topics Covered:
1. Executive Summary
2. Pediatric Neuroblastoma Treatment Market Characteristics
3. Pediatric Neuroblastoma Treatment Market Trends And Strategies
4. Pediatric Neuroblastoma Treatment Market - Macro Economic Scenario
4.1. COVID-19 Impact On Pediatric Neuroblastoma Treatment Market
4.2. Ukraine-Russia War Impact On Pediatric Neuroblastoma Treatment Market
4.3. Impact Of High Inflation On Pediatric Neuroblastoma Treatment Market
5. Pediatric Neuroblastoma Treatment Market Size And Growth
5.1. Global Pediatric Neuroblastoma Treatment Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Pediatric Neuroblastoma Treatment Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Pediatric Neuroblastoma Treatment Market Segmentation
6.1. Global Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Immunotherapy
- Chemotherapy
- Radiation Therapy
- Other Treatment Types
6.2. Global Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Low Risk
- Intermediate Risk
- High Risk
6.3. Global Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Hospitals
- Specialty Clinics
- Other End Users
7. Pediatric Neuroblastoma Treatment Market Regional And Country Analysis
7.1. Global Pediatric Neuroblastoma Treatment Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Pediatric Neuroblastoma Treatment Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/lfwto1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
